The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT02137226




Registration number
NCT02137226
Ethics application status
Date submitted
12/05/2014
Date registered
13/05/2014
Date last updated
19/01/2018

Titles & IDs
Public title
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Scientific title
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Secondary ID [1] 0 0
2012-002945-40
Secondary ID [2] 0 0
1297.2
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Arthritis, Rheumatoid 0 0
Condition category
Condition code
Musculoskeletal 0 0 0 0
Osteoarthritis
Inflammatory and Immune System 0 0 0 0
Rheumatoid arthritis

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - BI 695501
Treatment: Drugs - US-licensed Humira®

Experimental: BI 695501 - one injection every 2 weeks for 48 weeks (25 injections in total)

Active Comparator: US-licensed Humira® - one injection every 2 weeks for 48 weeks (25 injections in total)


Treatment: Drugs: BI 695501
BI 695501, every two weeks for 48 weeks (25 injections in total)

Treatment: Drugs: US-licensed Humira®
one injection every 2 weeks for 48 weeks (25 injections in total)

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
The Proportion of Patients Meeting the American College of Rheumatology 20% (ACR20) Response Criteria at Week 12 - The proportion of patients meeting the ACR20 response criteria was assessed. A patient had an ACR20 response if all of the following occurred: A = 20 % improvement in the swollen joint count (66 joints), A = 20 % improvement in the tender joint count (68 joints), A = 20 % improvement in at least three of the following assessments: Patient's assessment of pain, Patient's global assessment of disease activity (equivalent to the General Health component of the Disease Activity Score (DAS)), Physician's global assessment of disease activity, Patient's assessment of physical function, as measured by the Health Assessment Questionnaire - Disability Index (HAQ-DI) Acute phase reactant (C-reactive protein (CRP)).The Full Analysis Set contained all enrolled patients who were randomized to trial drug and who received at least one dose of trial drug and had all efficacy measures relevant for the co-primary efficacy endpoints measured at baseline and at least once post- baseline.
Timepoint [1] 0 0
Week 12
Primary outcome [2] 0 0
The Proportion of Patients Meeting ACR20 Response Criteria at Week 24 - ACR20 at Week 12 and Week 24 are standard outcome criteria that are widely accepted for regulatory purposes to demonstrate efficacy in treating the signs and symptoms of Rheumatoid arthritis (RA). The proportion of patients meeting the ACR20 response criteria was assessed at Week 12 and Week 24 to provide a robust comparison with US-licensed Humira® data. A patient had an ACR20 response if all of the following occurred: A = 20 % improvement in the swollen joint count (66 joints), A = 20 % improvement in the tender joint count (68 joints), A = 20 % improvement in at least three of the following assessments: Patient's assessment of pain, Patient's global assessment of disease activity (equivalent to the General Health component of the Disease Activity Score ([DAS]), Physician's global assessment of disease activity, Patient's assessment of physical function, as measured by the Health Assessment Questionnaire - Disability Index (HAQ-DI) Acute phase reactant (C-reactive protein [CRP]).
Timepoint [2] 0 0
Week 24
Secondary outcome [1] 0 0
Change From Baseline in Disease Activity Score 28 (DAS28) (Erythrocyte Sedimentation Rate [ESR]) at Week 12 and Week 24 - The DAS28 (ESR) score was derived using the following formulae:
DAS28 (ESR) = 0.56*v(TJC28) + 0.28*v(SJC28) + 0.014*(GH) + 0.7*ln(ESR)
Where:
TJC28 = 28 joint count for tenderness
SJC28 = 28 joint count for swelling
Ln (ESR) = natural logarithm of ESR
GH = General Health component of the DAS (patient's global assessment of disease activity). DAS28 values range from 2.0 to 10.0 while higher values mean a higher disease activity. Actual number of patient analysed (N) is mean number of subjects in the analysis set with DAS28(ESR) results computable across the multiply imputed data sets. It is 319.6, 317.1 for week 12 and 313.9, 315.1 for week 24 for BI 695501 and US-licensed Humira® respectively.
Timepoint [1] 0 0
Baseline, Week 12 and Week 24
Secondary outcome [2] 0 0
The Percentage of Patients With Investigator-assessed Drug-related Adverse Events (AEs) During the Treatment Phase - The analysis of AEs was based on the concept of treatment-emergent AEs (TEAEs). Thus, all AEs with an onset after the first dose of trial drug up to a period of ten weeks after the last dose of trial drug were assigned to the current treatment for evaluation. Investigator-assessed drug related AEs were AEs with a relationship to drug ticked "yes" according to the Investigator. Overall results are presented from Day 1 up to Week 58 and are based on the initial randomization groups. The comparison therefore focuses on patients who received BI 695501 continuously versus patients who received Humira® continuously for the long term assessment of safety. One patient was initially treated with Humira and discontinued prior to Week 24. This patient was mistakenly re randomized to BI 695501 but not treated. For safety this was counted in Humira not re-randomized group (as treated), and for other analysis sets, this patient was counted in the Humira to BI 695501 group (as randomized).
Timepoint [2] 0 0
From the first drug administration until 10 weeks after the last drug administration, up to 58 weeks

Eligibility
Key inclusion criteria
Inclusion criteria:

- All patients must sign and date an Informed Consent Form consistent with International
Conference on Harmonisation Good Clinical Practice (ICH GCP) guidelines and local
legislation prior to participation in the trial (i.e. prior to any trial procedures,
which include medication washout and restrictions) and be willing to follow the
protocol.

- Male or female participants, between 18 and 80 years of age, who have a diagnosis of
moderately to severely active Rheumatoid arthritis for at least 6 months as defined by
at least six swollen joints (66 joint count) and at least six tender joints (68 joint
count) at Screening and Baseline (Day 1), and either an Erythrocyte sedimentation rate
of >28 mm/hour OR a C-reactive protein (CRP) level >1.0 mg/dL (normal: <0.4 mg/dL) at
Screening. Patients must currently be receiving methotrexate (MTX) therapy.

- Current treatment for Rheumatoid arthritis on an outpatient basis:

1. Must be receiving and tolerating oral or parenteral MTX therapy at a dose of 15
to 25 mg per week (dose may be as low as 10 mg per week if the patient is unable
to tolerate a higher dose) for at least 12 weeks immediately prior to Day 1. The
dose and administration route should remain stable for at least 4 weeks prior to
Day 1 until Week 24. After Week 24 the administration route can be changed at the
investigator's discretion. Patients receiving a lower dose of MTX (10 to 14
mg/week) should be doing so as a result of a documented history of intolerance to
higher doses of MTX.

2. Patients must be willing to receive oral folic acid (at least 5 mg/week or as per
local practice) or folinic acid (at least 1 mg/week or as per local practice) or
equivalent during the entire trial (mandatory comedication for MTX treatment).

3. Disease modifying antirheumatic drug (DMARD) use will be restricted according to
guidelines listed in the trial protocol.

4. If receiving current treatment with oral corticosteroids (other than
intra-articular or parenteral), the dose must not exceed 10 mg/day prednisolone
or equivalent. During the 4 weeks prior to Baseline (Day 1) the dose must remain
stable.

5. Any concomitant non-steroidal anti-inflammatory drugs (NSAIDs) must be stable for
at least 2 weeks prior to Day 1.

6. Patients may be taking oral hydroxychloroquine provided that the dose is not
greater than 400 mg/day or chloroquine provided that the dose is not greater than
250 mg/day. These doses must have been stable for a minimum of 12 weeks prior to
Day 1. The hydroxychloroquine or chloroquine treatment will need to be continued
at a stable dose with the same formulation until the end of the trial.

- For participants of reproductive potential (males and females), a reliable means of
contraception has to be used throughout trial participation(acceptable methods of
birth control include for example birth control pills, intrauterine devices [IUDs],
surgical sterilization, vasectomized partner and double barrier method.. All patients
(males and females of child-bearing potential) must also agree to use an acceptable
method of contraception for 6 months following completion or discontinuation from the
trial medication.
Minimum age
18 Years
Maximum age
80 Years
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion criteria:

- ACR functional Class IV or wheelchair/bed bound.

- Primary or secondary immunodeficiency, including known history of HIV infection, or a
positive test at Screening.

- History of Tuberculosis, latent Tuberculosis, or positive purified protein derivative
test or interferon gamma-releasing assay .

- Known clinically significant coronary artery disease or significant cardiac
arrhythmias or severe congestive heart failure, or interstitial lung disease.

- Previous treatment with >=2 biologic agents.

- Previous treatment with adalimumab or adalimumab biosimilar.

- Current treatment or previous treatment with leflunomide within 8 weeks.

- History of a severe allergic reaction or anaphylactic reaction to a biological agent
or history of hypersensitivity to adalimumab or any component of the trial drug.

- History of cancer including solid tumors, hematologic malignancies, and carcinoma in
situ.

- Has evidence of positive serology for Hepatitis B virus or Hepatitis C virus

- Receipt of a live/attenuated vaccine within 12 weeks prior to the Screening Visit.
Patients who are expecting to receive any live virus or bacterial vaccinations during
the trial, or up to 3 months after the last dose of trial drug.

- Any treatment that, in the opinion of the investigator, may place the patient at
unacceptable risk during the trial.

- Patients with a significant disease other than Rheumatoid arthritis and/or a
significant uncontrolled disease (such as, but not limited to, nervous system, renal,
hepatic, endocrine, or gastrointestinal disorders). A significant disease is defined
as a disease which, in the opinion of the investigator, may (i) put the patient at
risk because of participation in the trial, or (ii) influence the results of the
trial, or (iii) cause concern regarding the patient's ability to participate in the
trial.

- Premenopausal, sexually active women who are pregnant or nursing, or are of
child-bearing potential and not practicing an acceptable method of birth control, or
do not plan to continue practicing an acceptable method of birth control throughout
the trial.

- History of, or current, inflammatory joint disease other than Rheumatoid arthritis or
other systemic autoimmune disorder.

- Diagnosis of juvenile idiopathic arthritis, and/or Rheumatoid arthritis before age 16.

- Any planned surgical procedure within 12 weeks prior to the Screening Visit or for the
duration of the trial.

- Known active infection of any kind (excluding fungal infections of nail beds), or any
major episode of infection requiring hospitalization or treatment with intravenous
anti infectives within 4 weeks of the Screening Visit or completion of oral
anti-infectives within 2 weeks of the Screening Visit.

- History of deep space/tissue infection within 52 weeks of the Screening Visit.

- History of serious infection or opportunistic infection in the last 2 years.

- Any neurological, vascular or systemic disorder that might affect any of the efficacy
assessments.

- Currently active alcohol or drug abuse or history of alcohol or drug abuse within 2
years of the Screening Visit.

- Treatment with intravenous Gamma Globulin or the Prosorba® Column within 6 months of
the Screening Visit.

- Treatment with intravenous, intramuscular, intra-articular and parenteral
corticosteroids within 6 weeks prior to Day 1 or throughout the trial.

- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >1.5 times upper
limit of normal.

- Hemoglobin <8.0 g/dL.

- Platelets <100,000/µL.

- Leukocyte count <4000/µL.

- Creatinine clearance <60 mL/min.

- Patients who are currently participating in another clinical trial or who have been
participating in another clinical trial with another investigational drug within a
minimum of 12 weeks or five half-lives (whichever is longer) of the drug prior to Day
1.

- Patients with a history of any clinically significant adverse reaction to murine or
chimeric proteins.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Idaho
Country [7] 0 0
United States of America
State/province [7] 0 0
Indiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Kansas
Country [9] 0 0
United States of America
State/province [9] 0 0
Louisiana
Country [10] 0 0
United States of America
State/province [10] 0 0
Maryland
Country [11] 0 0
United States of America
State/province [11] 0 0
Massachusetts
Country [12] 0 0
United States of America
State/province [12] 0 0
Michigan
Country [13] 0 0
United States of America
State/province [13] 0 0
Mississippi
Country [14] 0 0
United States of America
State/province [14] 0 0
Montana
Country [15] 0 0
United States of America
State/province [15] 0 0
Nebraska
Country [16] 0 0
United States of America
State/province [16] 0 0
New Jersey
Country [17] 0 0
United States of America
State/province [17] 0 0
New Mexico
Country [18] 0 0
United States of America
State/province [18] 0 0
New York
Country [19] 0 0
United States of America
State/province [19] 0 0
North Carolina
Country [20] 0 0
United States of America
State/province [20] 0 0
Ohio
Country [21] 0 0
United States of America
State/province [21] 0 0
Pennsylvania
Country [22] 0 0
United States of America
State/province [22] 0 0
South Carolina
Country [23] 0 0
United States of America
State/province [23] 0 0
Tennessee
Country [24] 0 0
United States of America
State/province [24] 0 0
Texas
Country [25] 0 0
United States of America
State/province [25] 0 0
Virginia
Country [26] 0 0
United States of America
State/province [26] 0 0
Washington
Country [27] 0 0
Bulgaria
State/province [27] 0 0
Plovdiv
Country [28] 0 0
Bulgaria
State/province [28] 0 0
Ruse
Country [29] 0 0
Bulgaria
State/province [29] 0 0
Shumen
Country [30] 0 0
Bulgaria
State/province [30] 0 0
Sofia
Country [31] 0 0
Bulgaria
State/province [31] 0 0
Varna
Country [32] 0 0
Bulgaria
State/province [32] 0 0
Veliko Tarnovo
Country [33] 0 0
Chile
State/province [33] 0 0
Osorno
Country [34] 0 0
Chile
State/province [34] 0 0
Puerto Varas
Country [35] 0 0
Chile
State/province [35] 0 0
Santiago
Country [36] 0 0
Chile
State/province [36] 0 0
Viña del Mar
Country [37] 0 0
Estonia
State/province [37] 0 0
Pärnu
Country [38] 0 0
Estonia
State/province [38] 0 0
Tartu
Country [39] 0 0
Germany
State/province [39] 0 0
Bad Doberan
Country [40] 0 0
Germany
State/province [40] 0 0
Bad Kreuznach
Country [41] 0 0
Germany
State/province [41] 0 0
Bad Nauheim
Country [42] 0 0
Germany
State/province [42] 0 0
Magdeburg
Country [43] 0 0
Hungary
State/province [43] 0 0
Szeged
Country [44] 0 0
Hungary
State/province [44] 0 0
Veszprem
Country [45] 0 0
Korea, Republic of
State/province [45] 0 0
Daegu
Country [46] 0 0
Korea, Republic of
State/province [46] 0 0
Daejeon
Country [47] 0 0
Korea, Republic of
State/province [47] 0 0
Seoul
Country [48] 0 0
Malaysia
State/province [48] 0 0
Kuantan
Country [49] 0 0
Malaysia
State/province [49] 0 0
Pulau Pinang
Country [50] 0 0
New Zealand
State/province [50] 0 0
Cantebury
Country [51] 0 0
Poland
State/province [51] 0 0
Bialystok
Country [52] 0 0
Poland
State/province [52] 0 0
Bydgoszcz
Country [53] 0 0
Poland
State/province [53] 0 0
Elblag
Country [54] 0 0
Poland
State/province [54] 0 0
Gdynia
Country [55] 0 0
Poland
State/province [55] 0 0
Grodzisk Mazowiecki
Country [56] 0 0
Poland
State/province [56] 0 0
Katowice
Country [57] 0 0
Poland
State/province [57] 0 0
Krakow
Country [58] 0 0
Poland
State/province [58] 0 0
Torun
Country [59] 0 0
Poland
State/province [59] 0 0
Warszawa
Country [60] 0 0
Poland
State/province [60] 0 0
Wroclaw
Country [61] 0 0
Russian Federation
State/province [61] 0 0
Kemerovo
Country [62] 0 0
Russian Federation
State/province [62] 0 0
Moscow
Country [63] 0 0
Russian Federation
State/province [63] 0 0
Petrozavodsk
Country [64] 0 0
Russian Federation
State/province [64] 0 0
Samara
Country [65] 0 0
Russian Federation
State/province [65] 0 0
Saratov
Country [66] 0 0
Russian Federation
State/province [66] 0 0
Stavropol
Country [67] 0 0
Russian Federation
State/province [67] 0 0
Yaroslavl
Country [68] 0 0
Serbia
State/province [68] 0 0
Belgrade
Country [69] 0 0
Serbia
State/province [69] 0 0
Niska Banja
Country [70] 0 0
Serbia
State/province [70] 0 0
Novi Sad
Country [71] 0 0
Serbia
State/province [71] 0 0
Sabac
Country [72] 0 0
Spain
State/province [72] 0 0
Barakaldo
Country [73] 0 0
Spain
State/province [73] 0 0
La Coruña
Country [74] 0 0
Spain
State/province [74] 0 0
Madrid
Country [75] 0 0
Spain
State/province [75] 0 0
Santiago de Compostela
Country [76] 0 0
Thailand
State/province [76] 0 0
Bangkoknoi
Country [77] 0 0
Thailand
State/province [77] 0 0
Hat Yai
Country [78] 0 0
Thailand
State/province [78] 0 0
Rajathevee
Country [79] 0 0
Ukraine
State/province [79] 0 0
Ivano-Frankivsk
Country [80] 0 0
Ukraine
State/province [80] 0 0
Kharkiv
Country [81] 0 0
Ukraine
State/province [81] 0 0
Kyiv
Country [82] 0 0
Ukraine
State/province [82] 0 0
Poltava
Country [83] 0 0
Ukraine
State/province [83] 0 0
Vinnytsia
Country [84] 0 0
Ukraine
State/province [84] 0 0
Zaporizhzhia

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Boehringer Ingelheim
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Primary Objective:

The primary objective of this trial is to establish an equivalence in efficacy between BI
695501 and US-licensed Humira® in patients with active Rheumatoid arthritis based on a
statistical comparison of the proportion of patients meeting American College of Rheumatology
20% (ACR20) response rate at Week 12 and ACR20 response rate at Week 24 between BI 695501 and
US-licensed Humira®.

Secondary Objectives:

The secondary objectives of this trial are to compare the efficacy, safety and immunogenicity
of BI 695501 and US-licensed Humira® in patients with active RA including those undergoing
the transition from US-licensed Humira® to BI 695501 after 24 weeks.
Trial website
https://clinicaltrials.gov/show/NCT02137226
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Boehringer Ingelheim
Address 0 0
Boehringer Ingelheim
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications